🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesGLP-1 and atrial fibrillation risk — November 2025 Page 3

GLP-1 and atrial fibrillation risk — November 2025

NurseLeah_Nash Mon, Oct 20, 2025 at 7:42 AM 39 replies 2,030 viewsPage 3 of 8
HPLC_Greg
Senior Member
1,890
8,901
Feb 2024
Research Triangle, NC
Oct 21, 2025 at 9:28 PM#11
Dr.RheumBOS said:
Vitamin deficiency cascade with cardiovascular risk: after 6+ months of reduced food intake, I developed a subtle but important pattern: low B12 →…

SUSTAIN-6 was the first CVOT to show cardiovascular benefit with semaglutide, relevant to cardiovascular risk. In 3,297 T2DM patients with high CV risk: MACE HR 0.74 (95% CI 0.58-0.95, p=0.02)[1].

Notable: the retinopathy signal in SUSTAIN-6 (HR 1.76) was subsequently attributed to rapid A1C reduction in patients with pre-existing retinopathy — not a direct drug effect. This has been confirmed in longer-term follow-up studies.

References:
[1] Marso SP, et al. N Engl J Med. 2016;375(19):1834-1844.
1 1SallyK_inj
Reply Quote Save Share Report
maya_sedona
Member
289
1,234
Sep 2024
Sedona, AZ
Oct 22, 2025 at 1:29 PM#12
marcus_mpls said:
Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history.

Saving this. It is the first explanation that did not require me to already understand it.

50 0NurseAsh_DET, BenResearch_OR, MikeKY_noInsulin and 47 others
Reply Quote Save Share Report
BenResearch_OR
Senior Member
2,456
11,234
Dec 2023
Oregon
Oct 23, 2025 at 5:29 AM#13
Dr.RheumBOS said:
Vitamin deficiency cascade with cardiovascular risk: after 6+ months of reduced food intake, I developed a subtle but important pattern: low B12 →…

NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).

From SELECT trial: MACE at 39 months — 6.5% semaglutide vs 8.0% placebo. ARR = 1.5%. NNT = 67 over 3.3 years.

Compare to established therapies:

InterventionNNTTimeframe
Semaglutide (MACE)673.3 years
Statins primary prevention (MI)~1005 years
Aspirin secondary prevention~772 years

These NNTs are clinically meaningful and comparable to accepted cardiovascular interventions.

49 24Dr.NateNeph, PharmD_Rodriguez, julia.endo and 46 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
josh_phd_bmore
Member
389
1,678
Jul 2024
Baltimore, MD
Oct 23, 2025 at 9:29 PM#14
NurseLeah_Nash said:
My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

Dizziness and cardiovascular risk: I was lightheaded for the first 3 weeks. Root cause was a combination of reduced caloric intake and mild dehydration.

Fix: minimum 80-100oz water daily, don't skip meals even if you're not hungry (eat small protein-rich snacks), and stand up slowly from sitting/lying positions. Also check your blood pressure — GLP-1-induced weight loss can make BP meds too strong, requiring dose reduction.

48 23KarenAZ_mom, zoe_NC, Dr.ObesityLA and 45 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Oct 24, 2025 at 1:29 PM#15

Moderator note: good thread. Keeping it here rather than moving it, because the question is general enough to be useful. Thread quality here is what the rules are for. Keep it up.

47 22PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 44 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register